714 related articles for article (PubMed ID: 26582515)
21. [Ventilator associated pneumonia: risk factors, diagnosis, treatment and prevention].
Pilvinis V; Stirbiene I
Medicina (Kaunas); 2003; 39(11):1057-64. PubMed ID: 14646458
[TBL] [Abstract][Full Text] [Related]
22. Bronchoalveolar interleukin-1 beta: a marker of bacterial burden in mechanically ventilated patients with community-acquired pneumonia.
Wu CL; Lee YL; Chang KM; Chang GC; King SL; Chiang CD; Niederman MS
Crit Care Med; 2003 Mar; 31(3):812-7. PubMed ID: 12626989
[TBL] [Abstract][Full Text] [Related]
23. Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance.
Fernández-Barat L; Ferrer M; De Rosa F; Gabarrús A; Esperatti M; Terraneo S; Rinaudo M; Li Bassi G; Torres A
J Infect; 2017 Feb; 74(2):142-152. PubMed ID: 27865895
[TBL] [Abstract][Full Text] [Related]
24. Cyclic di-GMP stimulates protective innate immunity in bacterial pneumonia.
Karaolis DK; Newstead MW; Zeng X; Hyodo M; Hayakawa Y; Bhan U; Liang H; Standiford TJ
Infect Immun; 2007 Oct; 75(10):4942-50. PubMed ID: 17646358
[TBL] [Abstract][Full Text] [Related]
25. Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010.
Nordmann P; Naas T; Fortineau N; Poirel L
Curr Opin Microbiol; 2007 Oct; 10(5):436-40. PubMed ID: 17765004
[TBL] [Abstract][Full Text] [Related]
26. STAT4 is a critical mediator of early innate immune responses against pulmonary Klebsiella infection.
Deng JC; Zeng X; Newstead M; Moore TA; Tsai WC; Thannickal VJ; Standiford TJ
J Immunol; 2004 Sep; 173(6):4075-83. PubMed ID: 15356157
[TBL] [Abstract][Full Text] [Related]
27. Cutting edge: myeloid differentiation factor 88 is essential for pulmonary host defense against Pseudomonas aeruginosa but not Staphylococcus aureus.
Skerrett SJ; Liggitt HD; Hajjar AM; Wilson CB
J Immunol; 2004 Mar; 172(6):3377-81. PubMed ID: 15004134
[TBL] [Abstract][Full Text] [Related]
28. Incidence and antimicrobial resistance trends in bloodstream infections caused by ESKAPE and Escherichia coli at a large teaching hospital in Rome, a 9-year analysis (2007-2015).
De Angelis G; Fiori B; Menchinelli G; D'Inzeo T; Liotti FM; Morandotti GA; Sanguinetti M; Posteraro B; Spanu T
Eur J Clin Microbiol Infect Dis; 2018 Sep; 37(9):1627-1636. PubMed ID: 29948360
[TBL] [Abstract][Full Text] [Related]
29. Impact of antibiotic-resistant bacteria on the outcome of ventilator-associated pneumonia.
Combes A; Luyt CE; Trouillet JL
Semin Respir Crit Care Med; 2006 Feb; 27(1):23-8. PubMed ID: 16508878
[TBL] [Abstract][Full Text] [Related]
30. Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo.
Yao Q; Wang J; Cui T; Yang Z; Su M; Zhao P; Yan H; Zhan Y; Yang H
Molecules; 2016 Jan; 21(1):62. PubMed ID: 26751436
[TBL] [Abstract][Full Text] [Related]
31. Recurrent wheezing in neonatal pneumonia is associated with combined infection with Respiratory Syncytial Virus and Staphylococcus aureus or Klebsiella pneumoniae.
Zhong Q; Feng H; Lu Q; Liu X; Zhao Q; Du Y; Zhang XH; Wang JR
Sci Rep; 2018 Jan; 8(1):995. PubMed ID: 29343795
[TBL] [Abstract][Full Text] [Related]
32. Acute Inflammatory Response of Patients with Pseudomonas aeruginosa Infections: A Prospective Study.
Gómez-Zorrilla S; Morandeira F; Castro MJ; Tubau F; Periche E; Cañizares R; Dominguez MA; Ariza J; Peña C
Microb Drug Resist; 2017 Jun; 23(4):523-530. PubMed ID: 27754817
[TBL] [Abstract][Full Text] [Related]
33. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.
Lepak AJ; Andes DR
Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072
[TBL] [Abstract][Full Text] [Related]
34. Pseudomonas aeruginosa Biofilms: Host Response and Clinical Implications in Lung Infections.
Maurice NM; Bedi B; Sadikot RT
Am J Respir Cell Mol Biol; 2018 Apr; 58(4):428-439. PubMed ID: 29372812
[TBL] [Abstract][Full Text] [Related]
35. [The impact of antibiotic use on hospital-acquired pneumonia: data of etiology tests].
Vitkauskiene A; Sakalauskas R; Dudzevicius V
Medicina (Kaunas); 2003; 39(3):254-9. PubMed ID: 12695638
[TBL] [Abstract][Full Text] [Related]
36. Early bacterial clearance from murine lungs. Species-dependent phagocyte response.
Rehm SR; Gross GN; Pierce AK
J Clin Invest; 1980 Aug; 66(2):194-9. PubMed ID: 6995480
[TBL] [Abstract][Full Text] [Related]
37. Prekallikrein inhibits innate immune signaling in the lung and impairs host defense during pneumosepsis in mice.
Ding C; Scicluna BP; Stroo I; Yang J; Roelofs JJ; de Boer OJ; de Vos AF; Nürnberg P; Revenko AS; Crosby J; Van't Veer C; van der Poll T
J Pathol; 2020 Jan; 250(1):95-106. PubMed ID: 31595971
[TBL] [Abstract][Full Text] [Related]
38. Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens.
Jean SS; Hsueh PR
Expert Opin Pharmacother; 2011 Oct; 12(14):2145-8. PubMed ID: 21895553
[TBL] [Abstract][Full Text] [Related]
39. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use.
MacDougall C; Harpe SE; Powell JP; Johnson CK; Edmond MB; Polk RE
Emerg Infect Dis; 2005 Aug; 11(8):1197-204. PubMed ID: 16102307
[TBL] [Abstract][Full Text] [Related]
40. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients.
Falagas ME; Rafailidis PI; Matthaiou DK; Virtzili S; Nikita D; Michalopoulos A
Int J Antimicrob Agents; 2008 Nov; 32(5):450-4. PubMed ID: 18768302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
